Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.54 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.54 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.54 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2525947 | 1.00 | TDP1 (0.56) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL8119333 | 1.00 | TDP1 (0.56) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL29051137 | 0.90 | KMT2A (0.54) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL29051134 | 0.87 | MEN1 (0.58) | KMT2ALMNACHRNB2CHRNA5CHRNA7 | |
| SCHEMBL14727179 | 0.84 | ALDH1A1 (0.55) | TDP1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL217123 | 0.84 | ALDH1A1 (0.55) | TDP1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL19892095 | 0.84 | ALDH1A1 (0.55) | TDP1KMT2ALMNAALDH1A1MAPT | |
| SCHEMBL6538786 | 0.84 | KMT2A (0.59) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL21215915 | 0.84 | LMNA (0.47) | TDP1KMT2ASLC6A2SLC6A3LMNA | |
| SCHEMBL21216020 | 0.84 | LMNA (0.47) | TDP1KMT2ASLC6A2SLC6A3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453657-B2 | Compounds for the treatment of parasitic infections | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-09-27 | — | — | US | disclosed |
| EP-3743419-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2022-09-14 | — | — | EP | disclosed |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-18 | — | — | US | disclosed |
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | AUSPEX PHARMACEUTICALS, INC. | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340361-A1 | PIPERIDINE INHIBITORS OF JANUS KINASE 3 | JAK2, JAK3, PAK3 | TDP1 2946/4885KMT2A 1262/4885SLC6A2 4828/4885 |
| US-11453657-B2 | Compounds for the treatment of parasitic infections | PIGO, SGMS2, ABCB11 | TDP1 4775/4885KMT2A 2592/4885SLC6A2 2059/4885 |
| US-20210047299-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF PARASITIC INFECTIONS | PIGO, ENPP2, THPO | TDP1 4763/4885KMT2A 2790/4885SLC6A2 2997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.